Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pharmacokinetics and Safety of Roledumab, a Fully Human Recombinant Monoclonal Anti-RhD Antibody, in RhD-negative Pregnant Woman Carrying an RhD-positive Foetus: a Phase IIb, Multicenter, Open-label Study

NCT02287896 is registered in ClinicalTrials.gov with Laboratoire français de Fractionnement et de Biotechnologies as lead sponsor.

NCT NCT02287896
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02287896 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pharmacokinetics and Safety of Roledumab, a Fully Human Recombinant Monoclonal Anti-RhD Antibody, in RhD-negative Pregnant Woman Carrying an RhD-positive Foetus: a Phase IIb, Multicenter, Open-label Study
Lead sponsor
Laboratoire français de Fractionnement et de Biotechnologies
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2014
Completion date
September 13, 2017
Enrollment
62 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

rh disease